CD151 expression marks atrial- and ventricular- differentiation from human induced pluripotent stem cells.

Autor: Nakanishi-Koakutsu M; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan.; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.; Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA., Miki K; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan. kenjimiki.prime@osaka-u.ac.jp.; Center for Organ Engineering, Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA. kenjimiki.prime@osaka-u.ac.jp.; Department of Surgery, Harvard Medical School, Boston, MA, 02114, USA. kenjimiki.prime@osaka-u.ac.jp.; Premium Research Institute for Human Metaverse Medicine, Osaka University, Suita, 565-0871, Japan. kenjimiki.prime@osaka-u.ac.jp., Naka Y; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan., Sasaki M; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan., Wakimizu T; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan., Napier SC; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan.; Global Advanced Platform, Takeda Pharmaceutical Company Limited, Fujisawa, 251-8555, Japan., Okubo C; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan., Narita M; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan., Nishikawa M; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan., Hata R; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan., Chonabayashi K; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan., Hotta A; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan., Imahashi K; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan.; Global Advanced Platform, Takeda Pharmaceutical Company Limited, Fujisawa, 251-8555, Japan., Nishimoto T; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan.; Orizuru Therapeutics Incorporated, Fujisawa, 251-8555, Japan., Yoshida Y; Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan. yoshinor@cira.kyoto-u.ac.jp.; Takeda-CiRA Joint program (T-CiRA), Fujisawa, 251-8555, Japan. yoshinor@cira.kyoto-u.ac.jp.
Jazyk: angličtina
Zdroj: Communications biology [Commun Biol] 2024 Feb 28; Vol. 7 (1), pp. 231. Date of Electronic Publication: 2024 Feb 28.
DOI: 10.1038/s42003-024-05809-2
Abstrakt: Current differentiation protocols for human induced pluripotent stem cells (hiPSCs) produce heterogeneous cardiomyocytes (CMs). Although chamber-specific CM selection using cell surface antigens enhances biomedical applications, a cell surface marker that accurately distinguishes between hiPSC-derived atrial CMs (ACMs) and ventricular CMs (VCMs) has not yet been identified. We have developed an approach for obtaining functional hiPSC-ACMs and -VCMs based on CD151 expression. For ACM differentiation, we found that ACMs are enriched in the CD151 low population and that CD151 expression is correlated with the expression of Notch4 and its ligands. Furthermore, Notch signaling inhibition followed by selecting the CD151 low population during atrial differentiation leads to the highly efficient generation of ACMs as evidenced by gene expression and electrophysiology. In contrast, for VCM differentiation, VCMs exhibiting a ventricular-related gene signature and uniform action potentials are enriched in the CD151 high population. Our findings enable the production of high-quality ACMs and VCMs appropriate for hiPSC-derived chamber-specific disease models and other applications.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje